Ultragenyx Pharmaceutical Inc.’s recently made public that its EVP and Chief Medical Officer Crombez Eric unloaded Company’s shares for reported $6262.0 on Apr 18 ’24. In the deal valued at $44.10 per share,142 shares were sold. As a result of this transaction, Crombez Eric now holds 48,785 shares worth roughly $2.15 million.
Then, Kassberg Thomas Richard sold 11,509 shares, generating $574,644 in total proceeds. Upon selling the shares at $49.93, the CBO & EVP now owns 252,823 shares.
Before that, Fust Matthew K sold 12,195 shares. Ultragenyx Pharmaceutical Inc. shares valued at $620,443 were divested by the Director at a price of $50.88 per share. As a result of the transaction, Fust Matthew K now holds 14,860 shares, worth roughly $0.65 million.
RBC Capital Mkts initiated its Ultragenyx Pharmaceutical Inc. [RARE] rating to an Outperform in a research note published on April 22, 2024; the price target was $77. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early December with a ‘”an Overweight”‘ rating. Evercore ISI revised its rating on June 06, 2023. It rated RARE as “an Outperform” which previously was an “an In-line”.
Price Performance Review of RARE
On Monday, Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE] saw its stock fall -0.50% to $44.02. Over the last five days, the stock has gained 0.76%. Ultragenyx Pharmaceutical Inc. shares have fallen nearly -7.95% since the year began. Nevertheless, the stocks have risen 3.67% over the past one year. While a 52-week high of $54.98 was reached on 03/01/24, a 52-week low of $31.52 was recorded on 04/19/24. SMA at 50 days reached $47.75, while 200 days put it at $42.13. A total of 0.63 million shares were traded, compared to the trading of 0.67 million shares in the previous session.
Levels Of Support And Resistance For RARE Stock
The 24-hour chart illustrates a support level at 43.51, which if violated will result in even more drops to 42.99. On the upside, there is a resistance level at 44.95. A further resistance level may holdings at 45.87. The Relative Strength Index (RSI) on the 14-day chart is 43.24, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.93, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.33%. Stochastics %K at 25.82% indicates the stock is a holding.
The most recent change occurred on April 26, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $114 price target.
